Unknown

Dataset Information

0

Enzyme-mediated methodology for the site-specific radiolabeling of antibodies based on catalyst-free click chemistry.


ABSTRACT: An enzyme- and click chemistry-mediated methodology for the site-selective radiolabeling of antibodies on the heavy chain glycans has been developed and validated. To this end, a model system based on the prostate specific membrane antigen-targeting antibody J591, the positron-emitting radiometal (89)Zr, and the chelator desferrioxamine has been employed. The methodology consists of four steps: (1) the removal of sugars on the heavy chain region of the antibody to expose terminal N-acetylglucosamine residues; (2) the incorporation of azide-modified N-acetylgalactosamine monosaccharides into the glycans of the antibody; (3) the catalyst-free click conjugation of desferrioxamine-modified dibenzocyclooctynes to the azide-bearing sugars; and (4) the radiolabeling of the chelator-modified antibody with (89)Zr. The site-selective labeling methodology has proven facile, reproducible, and robust, producing (89)Zr-labeled radioimmunoconjguates that display high stability and immunoreactivity in vitro (>95%) in addition to highly selective tumor uptake (67.5 ± 5.0%ID/g) and tumor-to-background contrast in athymic nude mice bearing PSMA-expressing subcutaneous LNCaP xenografts. Ultimately, this strategy could play a critical role in the development of novel well-defined and highly immunoreactive radioimmunoconjugates for both the laboratory and clinic.

SUBMITTER: Zeglis BM 

PROVIDER: S-EPMC3714844 | biostudies-literature | 2013 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Enzyme-mediated methodology for the site-specific radiolabeling of antibodies based on catalyst-free click chemistry.

Zeglis Brian M BM   Davis Charles B CB   Aggeler Robert R   Kang Hee Chol HC   Chen Aimei A   Agnew Brian J BJ   Lewis Jason S JS  

Bioconjugate chemistry 20130530 6


An enzyme- and click chemistry-mediated methodology for the site-selective radiolabeling of antibodies on the heavy chain glycans has been developed and validated. To this end, a model system based on the prostate specific membrane antigen-targeting antibody J591, the positron-emitting radiometal (89)Zr, and the chelator desferrioxamine has been employed. The methodology consists of four steps: (1) the removal of sugars on the heavy chain region of the antibody to expose terminal N-acetylglucosa  ...[more]

Similar Datasets

| S-EPMC4085725 | biostudies-literature
| S-EPMC4025793 | biostudies-other
| S-EPMC5321420 | biostudies-literature
| S-EPMC8356811 | biostudies-literature
| S-EPMC3384729 | biostudies-literature
| S-EPMC6150616 | biostudies-literature
| S-EPMC2836626 | biostudies-literature
| S-EPMC4538826 | biostudies-literature
| S-EPMC2664610 | biostudies-literature
| S-EPMC3368396 | biostudies-literature